Platelet Aggregation, β-Thromboglobulin and Platelet Factor 4 in Diabetes Mellitus and in Patients with Vasculopathy

Fritschi, J; Christe, M; Lämmle, Bernhard; Marbet, G A; Berger, W; Duckert, F

doi:10.1055/s-0038-1661186

Cited by 42 publications

(14 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Changes in the regulation of the arachidonic acid metab- olism resulting in increased proaggregatory thromboxane formation were reported [2,3,8,11], but could not be confirmed recently for type I diabetics with or without retinopa thy [12], a-Granule proteins such as 0-thromboglobulin ((3-TG) and platelet factor 4 (PF-4) are released during platelet activa tion [13]. Plasmatic concentrations of these proteins were found to be increased in dia betics [3,[14][15][16][17][18], reflecting a higher degree o f'in vivo' platelet activation. This has been shown for patients without microangiopathy and even more for newly diagnosed type I diabetics [19,20].…”

Section: Introductionmentioning

confidence: 99%

Elevated Platelet Activation in Type I Diabetics with Chronic Complications under Long-Term Near-Normoglycemic Control

Tschöepe

Ostermann²,

Huebinger³

et al. 1990

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

A prethrombotic state with altered, hyperactive platelets may contribute to the development of diabetic late complications. Whether increased platelet ‘in vivo’ activation can be reduced by tight metabolic control is controversial. We studied plasma markers of platelet activation in 64 long-term, microangiopathic type I diabetics after at least 18 months of intensive treatment for near-normoglycemia. Both platelet factor 4 and β-thromboglobulin proved to be significantly (p ≤ 0.05) elevated in comparison with healthy controls: 15.8 (sdf 2)/77.6 (sdf 1.9) vs. 8.9 (sdf 1.6)/45.1 (sdf 2) ng/ml (sdf = standard deviation factor). We found no significant correlations with any metabolic parameter (actual blood glucose, mean blood glucose, HbA 1 triglycerides, cholesterol) or with the duration of intensive treatment. It is therefore concluded, that platelet ‘in vivo’ activation takes place in type I diabetics even after long-term near-normoglycemic control. This deviation could be regarded as indicator of an additional risk for the development of vascular complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Elevated Platelet Activation in Type I Diabetics with Chronic Complications under Long-Term Near-Normoglycemic Control

Tschöepe

Ostermann²,

Huebinger³

et al. 1990

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

show abstract

“…Haemostatic abnormalities are common in diabetic patients [1][2][3]. It is thought that impaired balance be tween coagulation and fibrinolysis may encourage hypercoagulable tendency and lead to intravascular fibrin deposition which can contribute to the develop ment of vascular complications [4,5], Fibrin deposi tion and its organization markedly depend on factor XIII action.…”

Section: Introductionmentioning

confidence: 99%

Plasma Factor XIII and some other Haemostasis Parameters in Patients with Diabetic Angiopathy

Kłoczko¹,

Wojtukiewicz²,

Bielawiec³

et al. 1986

Acta Haematol

View full text Add to dashboard Cite

Since intravascular and endoparietal fibrin deposition is thought to be involved in the development of atherosclerosis, we measured factor XIII activity and its subunit ‘a’ and ‘b’ concentrations against a background of other haemostasis parameters in diabetics with angiopathy and in 2 control groups (healthy subjects and diabetics without vascular complications). Diabetics with angiopathy revealed a significant increase of factor XIII activity as well as its subunit concentrations. They also had significantly elevated antithrombin III, α₂ macroglobulin, α₁ antitrypsin, C\ inhibitor, fibrinogen, FDP concentrations and prolongation of euglobulin lysis time. The highest factor XIII levels were found in diabetics with renal failure. We suppose that increased factor XIII level and other observed changes of haemostasis in patients with diabetic angiopathy might promote intravascular and endoparietal fibrin deposition and contribute to the development of atherosclerotic complications of diabetes.

show abstract

“…PGEj has been reported to improve microcirculation in the peripheral capillaries (3). In addition, platelets of diabetic subjects show Improved Diabetic Mononeuropathy by PGEi increased adhesiveness and hypersensitivity to aggregating agents which may be involved in the development of vascular complications (10)(11)(12). PGEj is also known to inhibit coagulation of platelets induced by collagen or serotonin (6).…”

Section: Discussionmentioning

confidence: 99%

Immediate improvement of diabetic mononeuropathy after intravenous administration of prostaglandin E1.

et al. 1990

View full text Add to dashboard Cite

The effects of intravenously administered prostaglandin Ej (PGE,) on diabetic mononeuropathy was investigated in three patients with diabetic oculomotor palsy. PGEj (1.0-1.5 /tg/day) was intravenously administered every morning for 4 or 6 weeks. Diplopia, blepharoptosis and decreased range of ocular movement, which were observed on admission, immediately began to improve at 1-4 days after the beginning of the treatment. On the final day of the treatment, none of the above signs remained in the three cases. The present study suggests that improvement of intraneural microcirculation by PGE! administration results in an immediate recovery from diabetic oculomotor nerve palsy.

show abstract

Platelet Aggregation, β-Thromboglobulin and Platelet Factor 4 in Diabetes Mellitus and in Patients with Vasculopathy

Cited by 42 publications

References 2 publications

Elevated Platelet Activation in Type I Diabetics with Chronic Complications under Long-Term Near-Normoglycemic Control

Elevated Platelet Activation in Type I Diabetics with Chronic Complications under Long-Term Near-Normoglycemic Control

Plasma Factor XIII and some other Haemostasis Parameters in Patients with Diabetic Angiopathy

Immediate improvement of diabetic mononeuropathy after intravenous administration of prostaglandin E1.

Contact Info

Product

Resources

About